Beijing, China, October 14, 2025 — Gan & Lee Pharmaceuticals (hereinafter referred to as Gan & Lee, stock code: 603087.SH) hosted a dialogue and exchange meeting in Beijing with the Brazilian Ministry of Health.

Participants included Dr. Wei Chen, Chairman and CEO of Gan & Lee, Minister of Health, H.E. Alexandre Padilha, Vice President of the Fundação Oswaldo Cruz (Fiocruz) Dr. Priscila Ferraz Soares, Director of the Third Directorate of Anvisa, Daniela Marreco Cerqueira, Ambassador of Brazilian Embassy in Beijing, Marcos Galvão, and Minister-Counsellor of the Brazilian Embassy in China Mr. João Batista do Nascimento Magalhães, exchanged in-depth views on introducing Gan & Lee’s innovative medicines into the Brazil’s public health system.

Gan & Lee subsequently signed a Memorandum of Understanding (MoU) with Fiocruz, a public institution directly under the Brazilian Ministry of Health. The MoU covers several of Gan & Lee’s late-stage innovative products, including the once-weekly ultra-long-acting insulin analog —— GZR4, the fixed-ratio once-weekly basal insulin/GLP-1RA combination—— GZR102, and novel therapies for oncology and autoimmune diseases developed based on Gan & Lee’s advanced PROTAC technology platform. The signing ceremony was witnessed by Minister Alexandre Padilha.

Also in attendance were key representatives including: Deputy Secretary of Science, Technology, and Innovation and of the Health Economic-Industrial Complex, Eduardo Jorge Valadares, Special Advisor, Fábio Manzini, Special Advisor for International Affairs (AISA), Marise Ribeiro Nogueira, Advisor for International Affairs of the Secretariat of Science, Technology, and Innovation and of the Health Economic-Industrial Complex, Tássia dos Santos Reis Soares, Head of the Health, Education, and Social Issues Department of Brazilian Embassy, Helena Melchionna and Ms. Gai Liu, Head of the International Business Department of Gan & Lee.

GZR4 Recognized for Outstanding Clinical Value — MoU Signed to Advance Collaboration

During the meeting, Gan & Lee introduced its self-developed innovative product, GZR4, a once-weekly ultra-long-acting insulin analog. The product’s unique molecular design and excellent clinical efficacy and safety data drew strong interest from the Brazilian delegation. GZR4 maintains stable glucose control for seven consecutive days with just one injection per week, significantly improving convenience, adherence, and long-term glycemic management for patients. This innovation addresses a major unmet need in diabetes care by reducing the burden of daily insulin injections.

Given GZR4’s strong clinical value and market potential, both parties formally signed a Memorandum of Understanding, establishing a framework for collaboration and taking a key step toward making this innovative therapy accessible to Brazilian patients in the near future.

Expanding Access to Innovative Therapies — Exploring New Avenues for Cooperation

Minister Alexandre Padilha expressed high appreciation for the previous collaboration between Gan & Lee and Fiocruz. He emphasized that the Brazilian Ministry of Health will continue to support both parties in deepening cooperation in insulin production, clinical research, and new technology development — including potential future projects involving ultra-long-acting insulins and combination formulations.

Dr. Priscila Ferraz Soares, Vice President of the Fundação Oswaldo Cruz (Fiocruz), stated that the foundation looks forward to expanding collaboration with Gan & Lee in the field of high-tech innovative drugs, accelerating local clinical trials in Brazil, and promoting the simultaneous global development of innovative therapies. She noted that this partnership would enhance local production capacity and enable earlier access for Brazilian patients, contributing to the overall advancement of Brazil’s public health system.

Advancing Global Innovation — Bringing Breakthrough Therapies to Patients Worldwide

During the discussion, Dr. Wei Chen, Chairman and CEO of Gan & Lee, praised the significance of this collaboration. He stated that the dialogue with the Brazilian Ministry of Health provides Gan & Lee with an important platform to better understand the needs of emerging markets and to showcase China’s innovative R&D capabilities to the world.

Dr. Chen emphasized that the PDP glargine insulin project marked the successful completion of the “1.0” stage of China–Brazil pharmaceutical cooperation. The new partnership centered around GZR4 and GZR102 signifies the beginning of “2.0” — moving from product introduction to joint development and innovation, and deepening strategic collaboration in biomedical science and technology between China and Brazil.

Looking ahead, Gan & Lee will continue to monitor global market trends — including Brazil — and actively explore potential cooperation opportunities. Guided by its mission to enhance global patient access to quality medicines, Gan & Lee will advance the worldwide development of its innovative therapies, adapt to regional healthcare needs and policy environments, and ensure that cutting-edge medicines benefit patients across more countries and regions.

About GZR4 Injection

Gan & Lee Pharmaceuticals' independently developed GZR4 injection is an ultra-long-acting weekly insulin preparation that is expected to provide more stable glucose-lowering effects and reduced intra- or inter-day blood glucose variability. GZR4 is anticipated to help patients with diabetes overcome injection barriers, enable earlier initiation of insulin therapy, optimize long-term diabetes management, and enhance patients' quality of life via once-weekly subcutaneous injection. Early clinical findings indicate that GZR4 demonstrates comparable reduction in HbA1c to insulin degludec in patients with inadequate glycemic control through oral antidiabetic medications. Currently, the global development of GZR4 has entered the Phase 3 clinical trial stage.

About GZR102 Injection

Gan & Lee Pharmaceuticals' proprietary GZR102 injection is a fixed-ratio once-weekly basal insulin/GLP-1RA combination, composed of the weekly insulin formulation GZR4 and the GLP-1RA bofanglutide (GZR18) in a fixed ratio. As a once-weekly subcutaneous formulation, GZR102 employs an innovative design to maximize the synergistic effects of both components. The insulin/GLP-1RA combination addresses multiple pathophysiological defects in T2DM, demonstrating enhanced glycemic control with reduced daily insulin requirements while mitigating adverse effects such as hypoglycemia and weight gain - positioning it as a potentially optimal therapeutic option that is effective, safe, and convenient for diabetes patients. GZR102 has now entered phase 2 clinical development globally.

About the PDP Program

The PDP program is a cornerstone initiative of Brazil's National Public Health System. Its core objective is to secure the long-term and stable supply of essential medicines by strengthening the country's healthcare infrastructure. Under the program's mechanism, Brazil's public healthcare system commits to long-term procurement in exchange for multinational pharmaceutical companies transferring advanced product technologies, thereby establishing a complete local manufacturing ecosystem in Brazil.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.